Clinical relevance of local renin angiotensin systems

Frontiers in Endocrinology

Volumn 5, Issue JUL, 2014, Pages

  Campbell, Duncan J ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin; Angiotensin converting enzyme; Angiotensinogen; Chymase; Renin

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSINOGEN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KALLIKREIN; MEMBRANE METALLOENDOPEPTIDASE;

BLOOD PRESSURE MONITORING; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; NONHUMAN; NOTE; PREGNANCY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 84905401789     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00113     Document Type: Note

References (67)

1. Campbell DJ. The site of angiotensin production. J Hypertens (1985) 3:199-207. doi: 10.1097/00004872-198506000-00002
2. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest (1987) 79:1-6. doi:10.1172/JCI112768
3. Admiraal PJJ, Derkx FHM, Danser AHJ, Pieterman H, Schalekamp MADH. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension (1990) 15:44-55. doi:10.1161/01.HYP.15.1.44
4. Campbell DJ. Angiotensin II generation in vivo: does it involve enzymes other than renin and angiotensin-converting enzyme? J Renin Angiotensin Aldosterone Syst (2012) 13:314-6. doi:10.1177/1470320312447162
5. Binger KJ, Muller DN. Autophagy and the (pro)renin receptor. Front Endocrinol (2013) 4:155. doi:10.3389/fendo.2013.00155
6. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the angiotensin converting enzyme 2-angiotensin (1-7)-Mas receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (2014) 4:201. doi:10.3389/fendo.2013.00201
7. De Mello WC, Frohlich ED. Clinical perspectives and fundamental aspects of local cardiovascular and renal renin-angiotensin systems. Front Endocrinol (2014) 5:16. doi:10.3389/fendo.2014.00016
8. Zhuo JL, Ferrao FM, Zheng Y, Li XC. New frontiers in the intrarenal renin-angiotensin system: a critical review of classical and new paradigms. Front Endocrinol (2013) 4:166. doi:10.3389/fendo.2013.00166
9. Wright JW, Kawas LH, Harding JW. A role for the brain RAS in Alzheimer's and Parkinson's diseases. Front Endocrinol (2013) 4:158. doi:10.3389/fendo.2013.00158
10. Aroor AR, Demarco VG, Jia G, Sun Z, Nistala R, Meininger GA, et al. The role of tissue renin-angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (2013) 4:161. doi:10.3389/fendo.2013.00161
11. Rodgers KE, Dizerega GS. Contribution of the local RAS to hematopoietic function: a novel therapeutic target. Front Endocrinol (2013) 4:157. doi:10.3389/fendo.2013.00157
12. Herr D, Bekes I, Wulff C. Local renin-angiotensin system in the reproductive system. Front Endocrinol (2013) 4:150. doi:10.3389/fendo.2013.00150
13. Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest (1986) 78:31-9. doi:10.1172/JCI112566
14. Campbell DJ, Habener JF. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology (1987) 121:1616-26. doi:10.1210/endo-121-5-1616
15. Campbell DJ, Habener JF. Hybridization in situ studies of angiotensinogen gene expression in rat adrenal and lung. Endocrinology (1989) 124:218-22. doi:10.1210/endo-124-1-218
16. Campbell DJ, Sernia C, Thomas WG, Oldfield BJ. Immunocytochemical localization of angiotensinogen in rat brain: dependence of neuronal immunoreactivity on method of tissue processing. J Neuroendocrinol (1991) 3:653-60. doi:10.1111/j.1365-2826.1991.tb00330.x
17. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension (2012) 60:444-50. doi:10.1161/HYPERTENSIONAHA.112.196352
18. Moreno C, Hoffman M, Stodola TJ, Didier DN, Lazar J, Geurts AM, et al. Creation and characterization of a renin knockout rat. Hypertension (2011) 57:614-9. doi:10.1161/HYPERTENSIONAHA.110.163840
19. Yanai K, Saito T, Kakinuma Y, Kon Y, Hirota K, Taniguchi-Yanai K, et al. Renin-dependent cardiovascular functions and renin-independent blood- brain barrier functions revealed by renin-deficient mice. J Biol Chem (2000) 275:5-8. doi:10.1074/jbc.275.1.5
20. Gribouval O, Moriniere V, Pawtowski A, Arrondel C, Sallinen SL, Saloranta C, et al. Spectrum of mutations in the renin-angiotensin system genes in autosomal recessive renal tubular dysgenesis. Hum Mutat (2012) 33:316-26. doi:10.1002/humu.21661
21. Niimura F, Labosky PA, Kakuchi J, Okubo S, Yoshida H, Oikawa T, et al. Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest (1995) 96:2947-54. doi:10.1172/JCI118366
22. Tsuchida S, Matsusaka T, Chen XM, Okubo S, Niimura F, Nishimura H, et al. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest (1998) 101:755-60. doi:10.1172/JCI1899
23. Esther CR Jr., Howard TE, Marino EM, Goddard JM, Capecchi MR, Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest (1996) 74:953-65.
24. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension (1991) 18:763-73. doi:10.1161/01.HYP.18.6.763
25. Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, et al. Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol (2012) 23:1181-9. doi:10.1681/ASN.2011121159
26. Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, Giani JF, Nguyen MT, Riquier-Brison AD, et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest (2013) 123:2011-23. doi:10.1172/JCI65460
27. Campbell DJ, Alexiou T, Xiao HD, Fuchs S, McKinley MJ, Corvol P, et al. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension (2004) 43:854-9. doi:10.1161/01.HYP.0000119190.06968.f1
28. Alexiou T, Boon WM, Denton DA, Di Nicolantonio R, Walker LL, McKinley MJ, et al. Angiotensinogen and angiotensin converting enzyme gene copy number and angiotensin and bradykinin peptide levels in mice. J Hypertens (2005) 23:945-54. doi:10.1097/01.hjh.0000166834.32817.41
29. Textor SC, Brunner HR, Gavras H. Converting enzyme inhibition during chronic angiotensin II infusion in rats. Evidence against a nonangiotensin mechanism. Hypertension (1981) 3:269-76. doi:10.1161/01.HYP.3.2.269
30. Mizelle HL, Hall JE, Woods LL. Interactions between angiotensin II and renal nerves during chronic sodium deprivation. Am J Physiol Renal Physiol (1988) 255:F823-7.
31. Shoback DM, Williams GH, Hollenberg NK, Davies RO, Moore TJ, Dluhy RG. Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man. J Clin Endocrinol Metab (1983) 57:764-70. doi:10.1210/jcem-57-4-764
32. Koletsky RJ, Gordon MB, LeBoff MS, Moore TJ, Dluhy RG, Hollenberg NK, et al. Captopril enhances vascular and adrenal responsiveness to angiotensin II in essential hypertension. Clin Sci (1984) 66:299-305.
33. Hannedouche T, Ikeni A, Marques LP, Natov S, Dechaux M, Schmitt F, et al. Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. J Cardiovasc Pharmacol (1992) 19(Suppl 6):S25-7. doi:10.1097/00005344-199219006-00005
34. Campbell DJ. Do intravenous and subcutaneous angiotensin II administration increase blood pressure by different mechanisms? Clin Exp Pharmacol Physiol (2013) 40:560-70. doi:10.1111/1440-1681.12085
35. Campbell DJ, Xiao H, Fuchs S, Bernstein KE. Genetic models provide unique insight into angiotensin and bradykinin peptides in the extravascular compartment of the heart in vivo. Clin Exp Pharmacol Physiol (2009) 36:547-53. doi:10.1111/j.1440-1681.2008.05106.x
36. Tian XL, Pinto YM, Costerousse O, Franz WM, Lippoldt A, Hoffmann S, et al. Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats. Hum Mol Genet (2004) 13:1441-50. doi:10.1093/hmg/ddh147
37. Hagaman JR, Moyer JS, Bachman ES, Sibony M, Magyar PL, Welch JE, et al. Angiotensin-converting enzyme and male fertility. Proc Natl Acad Sci U S A (1998) 95:2552-7. doi:10.1073/pnas.95.5.2552
38. Erdos EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension (1990) 16:363-70. doi:10.1161/01.HYP.16.4.363
39. Ganten D, Hermann K, Bayer C, Unger T, Lang RE. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science (1983) 221:869-71. doi:10.1126/science.6879184
40. Chappell MC, Brosnihan KB, Diz DI, Ferrario CM. Identification of angiotensin-(1-7) in rat brain. Evidence for differential processing of angiotensin peptides. J Biol Chem (1989) 264:16518-23.
41. Lawrence AC, Clarke IJ, Campbell DJ. Angiotensin peptides in brain and pituitary of rat and sheep. J Neuroendocrinol (1992) 4:237-44. doi:10.1111/j.1365-2826.1992.tb00165.x
42. Senanayake PD, Moriguchi A, Kumagai H, Ganten D, Ferrario CM, Brosnihan KB. Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides (1994) 15:919-26. doi:10.1016/0196-9781(94)90051-5
43. Svensson P, de Faire U, Sleight P, Yusuf S, Östergren J. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension (2001) 38:e28-32. doi:10.1161/hy1101.099502
44. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension (2001) 38:1382-7. doi:10.1161/hy1201.100589
45. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension (2001) 37:1047-52. doi:10.1161/01.HYP.37.4.1047
46. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int (2005) 68(Suppl 99):S57-65. doi:10.1111/j.1523-1755.2005.09911.x
47. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 372:547-53. doi:10.1016/S0140-6736(08)61236-2
48. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 358:1547-59. doi:10.1056/NEJMoa0801317
49. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767-71. doi:10.1016/S0140-6736(03)14283-3
50. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 349:1893-906. doi:10.1056/NEJMoa032292
51. Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J (2011) 32:1227-34. doi:10.1093/eurheartj/ehq522
52. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 367:2204-13. doi:10.1056/NEJMoa1208799
53. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA (2013) 309:1125-35. doi:10.1001/jama.2013.1954
54. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure - Role of kinins and angiotensin II type 2 receptors. J Clin Invest (1997) 99:1926-35. doi:10.1172/JCI119360
55. Koid SS, Ziogas J, Campbell DJ. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism. Hypertension (2014) 63:768-73. doi:10.1161/HYPERTENSIONAHA.113.02902
56. Ménard J, Campbell DJ, Azizi M, Gonzales M-F. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation (1997) 96:3072-8. doi:10.1161/01.CIR.96.9.3072
57. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension (1994) 23:439-49. doi:10.1161/01.HYP.23.4.439
58. Zeitz CJ, Campbell DJ, Horowitz JD. Myocardial uptake and biochemical and hemodynamic effects of ACE inhibitors in humans. Hypertension (2003) 41:482-7. doi:10.1161/01.HYP.0000054976.67487.08
59. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev (1995) 47:25-49.
60. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation (1997) 95:1115-8. doi:10.1161/01.CIR.95.5.1115
61. Gainer JV, Morrow JD, Lovelend A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med (1998) 339:1285-92. doi:10.1056/NEJM199810293391804
62. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation (2005) 111:315-20. doi:10.1161/01.CIR.0000153269.07762.3B
63. Campbell DJ, Zhang Y, Kelly DJ, Gilbert RE, McCarthy DJ, Shi W, et al. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. Clin Exp Pharmacol Physiol (2011) 38:623-31. doi:10.1111/j.1440-1681.2011.05572.x
64. Azizi M, Chatellier G, Guyene T-T, Murieta-Geoffroy D, Ménard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation (1995) 92:825-34. doi:10.1161/01.CIR.92.4.825
65. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol (2004) 15:3126-33. doi:10.1097/01.ASN.0000146686.35541.29
66. Campbell DJ, Anastasopoulos F, Duncan A-M, James GM, Kladis A, Briscoe TA. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther (1998) 287:567-77.
67. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res (1992) 71:1501-7. doi:10.1161/01.RES.71.6.1501